Enanta CEO Jay Luly To Retire By February 1 After 23 Years, As Board Creates A COO Job
Tara Kieffer becomes Enanta's first-ever Chief Operating Officer while the board searches inside and outside for a CEO successor.
Enanta Pharmaceuticals CEO Jay Luly, 70, plans to retire by February 1, 2027 after 23 years in the job, the company said Wednesday. The board also named Tara Kieffer to a newly created Chief Operating Officer role and has started a search for his successor.
A search inside and out
Enanta, a biotechnology company that discovers small molecule drugs for virology and immunology, said its board has begun a comprehensive search for a new CEO. Both internal and external candidates are under consideration.
Luly is to stay on as a strategic advisor for the rest of 2027, and the company expects to sign an agreement with him for that service. In the press release, he said that after 43 years in the pharmaceutical and biotechnology industries, "the time is right for me to begin my retirement from full-time executive leadership."
Chairman Bruce Carter credited Luly with helping bring forward cures for hepatitis C, as well as potential treatments for RSV and immunologic diseases.
Kieffer's new operating role
Kieffer, 48, joined Enanta in 2020 and most recently served as its Chief Product Strategy Officer. Before that she spent 16 years at Vertex Pharmaceuticals in research, clinical development, integrated program management and business development.
As COO she will help drive operational execution across the business and work with the leadership team on strategic priorities. She has not entered into any material plan, contract or arrangement in connection with the appointment, the filing says.
Royalties fund the pipeline
Enanta discovered glecaprevir, the hepatitis C antiviral AbbVie sells in MAVYRET in the US and MAVIRET elsewhere, and it earns royalties on those sales. Substantially all of its royalty revenue since August 2017 has come from that treatment, which helps fund operations.
Its own work centers on two clinical-stage respiratory syncytial virus candidates and early-stage oral drugs for type 2 inflammatory diseases. As of September 30, 2025, it held $188.9 million in cash, cash equivalents and short-term marketable securities.
The board's choice of a CEO, internal or external, is due before Luly's February 1, 2027 retirement deadline.
Sources
- 8-K Filing — ENANTA PHARMACEUTICALS INC (ENTA) — SEC EDGAR
- Exhibit d160214dex991.htm — ENANTA PHARMACEUTICALS INC 8-K exhibit — SEC EDGAR
- Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership – Company Announcement - FT.com — Financial Times